Chemistry:EIDD-1723
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt; Pregn-4-ene-3,20-dione 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt |
| Drug class | Neurosteroid |
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C22H32NNa2O6P |
| Molar mass | 483.452 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
EIDD-1723, also known as EPRX-01723 or as progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt, is a synthetic, water-soluble analogue of progesterone and a neurosteroid which was developed for the potential treatment of traumatic brain injury.[1][2] It is a rapidly converted prodrug of EIDD-036 (EPRX-036; progesterone 20-oxime), which is considered to be the active form of the agent.[1] Previous C3 and C20 oxime derivatives of progesterone, such as P1-185 (progesterone 3-O-(L-valine)-E-oxime), were also developed and studied prior to EIDD-1723.[3][4]
See also
- List of neurosteroids § Inhibitory > Synthetic > Pregnanes
- List of progestogen esters § Oximes of progesterone derivatives
References
- ↑ 1.0 1.1 "Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats". Neuropharmacology 109: 148–158. October 2016. doi:10.1016/j.neuropharm.2016.05.017. PMID 27267687.
- ↑ Guthrie, D. B., Lockwood, M. A., Natchus, M. G., Liotta, D. C., Stein, D. G., & Sayeed, I. (2017). U.S. Patent No. 9,802,978. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US9802978B2/en
- ↑ "Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury". J. Med. Chem. 52 (19): 6012–23. October 2009. doi:10.1021/jm900712n. PMID 19791804.
- ↑ "Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury". ACS Med Chem Lett 3 (5): 362–6. May 2012. doi:10.1021/ml200303r. PMID 24900479.
 |  |
